Full text is available at the source.
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
How once-weekly injectable semaglutide works for long-term weight control
AI simplified
Abstract
Once-weekly subcutaneous semaglutide 2.4 mg is the most efficacious medication approved for chronic weight management.
- Semaglutide is associated with sustained double-digit reductions in percentage body weight over 1- to 2-year treatment periods.
- It shows a similar safety and tolerability profile to other glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
- The treatment may significantly enhance clinical strategies for managing weight in patients with and without type 2 diabetes.
- However, the relatively high cost could limit patient access to this treatment.
- Further research is needed to explore the cost-effectiveness of semaglutide 2.4 mg.
AI simplified